Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets)

CNW/ - Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") is pleased to announce the successful conclusion of ...
Medical Xpress

Treatment-free remission for chronic myeloid leukemia

Leukemias are cancers of the blood cells. Chronic myelogenous leukemia (CML) is an uncommon type of cancer of the bone marrow, which produces blood cells. "Myelogenous" refers to the type of blood ...
Cancer Therapy Advisor

FDA Approves Cavhanza, an ODT Formulation of Nilotinib for Ph+ CML

Clinical trial data demonstrate that Cavhanza can be taken with or without food, offering patients greater administration convenience.
Taiwan News

Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML

These results provide longer-term evidence that Scemblix demonstrated increasingly superior molecular responses at week 144 compared with established tyrosine kinase inhibitors (TKIs), strengthening ...
MedPage Today

When CML Patients Stop TKI Therapy: What are the Cost Savings?

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...
Cure Today

Chronic Myeloid Leukemia: From Diagnosis to Ongoing Management

CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...